- Home
- ELOX vs CNTX Comparison
ELOX vs CNTX Comparison
Compare ELOX & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELOX | CNTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 47.7M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELOX | CNTX |
|---|---|---|
| Price | $12.89 | $0.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $37.50 | $4.14 |
| AVG Volume (30 Days) | 21.3K | ★ 1.2M |
| Earning Date | 08-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.67 | 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.00 | $0.18 |
| 52 Week High | $23.40 | $3.62 |
Technical Indicators
Market Signals| Indicator | ELOX | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 35.39 |
| Support Level | $12.47 | $0.18 |
| Resistance Level | $14.65 | $0.36 |
| Average True Range (ATR) | 0.95 | 0.02 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 54.27 | 14.03 |
Price Performance
Historical ComparisonAbout ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.